Shots:
- The EC has approved Cenrifki (PO, QD) for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last 2yrs.
- Approval was backed by P-III (HERCULES) trial (vs PBO) in non-relapsing SPMS (nrSPMS) & supporting data from P-III (GEMINI 1 & 2) studies (vs teriflunomide) in relapsing MS, with HERCULES demonstrating delayed onset of disability progression
- Cenrifki is an oral, brain-penetrant BTK inhibitor, which will be commercially available in Germany in 2026, supported by the required Risk Management Program and robust Patient Support Program
Ref: Globenewswire | Image: Sanofi | Press Release
Related News: The MHLW Approves Sanofi’s Sarclisa SC Formulation to Treat Multiple Myeloma (MM)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
